Opinion|Videos|July 12, 2024
PERSEUS Trial Findings at EHA 2024
Joseph Mikhael, MD, discusses the PERSEUS trial findings presented at EHA 2024.
Episodes in this series
Video content above is prompted by the following:
- Discuss the data presented at the European Hematology Association 2024 (EHA 2024) Hybrid Congress on minimal residual disease (MRD) in the PERSEUS trial of daratumumab plus bortezomib, lenalidomide, and dexamethasone (D-VRd) induction/consolidation followed by daratumumab/lenalidomide (D-R) in patients with newly diagnosed multiple myeloma.
- What was the objective of this study?
- How was this study designed/what methodology was used?
- What results were presented?
- Please provide your key takeaways from this study. How might these findings impact the management of patients with multiple myeloma?
- How have the criteria for multiple myeloma patients to be considered transplant-eligible or -ineligible evolved in recent history? How do you evaluate transplant eligibility in your practice?
Related to this article
A network meta-analysis found vibegron outperformed mirabegron and tolterodine on several OAB efficacy measures but had higher odds of adverse events.
A US modeling study found tirzepatide and semaglutide cost-effective for MASH, while resmetirom exceeded the $100,000/QALY threshold.
Panelists say drug price negotiation, Medicaid changes, prior authorization, and 340B reform strain community oncology.
Symptom-tracking tools may improve awareness and patient-clinician communication but can also add stress.
Payers cover novel cancer drugs but not the staffing, training, and monitoring to deliver them, leaving practices to absorb costs.
The 2026 COA Payer Exchange and Innovation Summit began with a panel on AI and the ever-changing digital infrastructure in community oncology.
Expert panel discussions covered AI and community access, chronic lymphocytic leukemia, myeloma, and breast and lung cancers.
Longer undetectable hepatitis D RNA on bulevirtide predicts durable suppression off therapy, but rebound and ALT flares rise, especially in cirrhosis.
Trending on AJMC
1
Medicare Cap Eases Patient Costs as Negotiation Squeezes Practices
2
Vibegron Outranks Mirabegron, Tolterodine on Several OAB Measures
3
PBM Satisfaction Stalls as Net Promoter Score Turns Negative
4
IRA, 340B, Medicaid: The Policy Pressures on Community Oncology
5